ArticleFrontiers in pharmacology2026
Dynamic kinetics of graft-derived cell-free DNA and personalized tacrolimus target ranges for acute rejection monitoring in pediatric liver transplantation.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acute rejection remains the most common complication during the early post-transplantation period for pediatric patients. Given the limitations of current diagnostic strategies, there is an urgent need to develop accurate and noninvasive biomarkers for allograft monitoring. Tacrolimus-based immunosuppression represents the cornerstone regimen following liver transplantation. However, for pediatric patients, current evidence remains insufficient to establish well-defined therapeutic target ranges for personalized tacrolimus therapy in pediatric patients. We investigated perioperative graft-derived cell-free DNA (GcfDNA) kinetics in pediatric recipients to establish the utility of GcfDNA for monitoring acute rejection and to explore the tacrolimus target concentration range in this population. Methods: Forty children (age ≤ 3 years) with biliary atresia who underwent liver transplantation were enrolled. All received a tacrolimus-based immunosuppressive regimen on postoperative day (POD) 1 and were followed for at least 1 month. GcfDNA levels were measured by droplet digital PCR. Results: GcfDNA (%) declined significantly during the first month. Median percentages on POD 1, 7, 14, 21, and 28 were 41.40%, 12.93%, 6.86%, 5.95%, and 3.23%, respectively. The acute rejection group maintained higher GcfDNA levels, with significant differences observed at POD 14, 21, and 28 ( Conclusion: We suggest that GcfDNA may serve as a potential biomarker for acute rejection monitoring in pediatric liver transplantation, with an exploratory predictive cutoff value of 10.21% identified in this single-center cohort. Our findings also tentatively point to a minimal effective tacrolimus C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.